India’s pharmaceutical industry may be targeting a $130-billion future by 2030, but a growing operational bottleneck threatens to slow its march: mounting manufacturing incidents, delayed investigations and compliance processes that are eating into production time and leadership bandwidth.
A new white paper by Vector Consulting Group, titled The compliance spiral in pharma manufacturing, has flagged the scale of the problem across multiple mid- to large-scale, USFDA-approved formulation plants in India.
The findings point to a troubling pattern: incidents remain unresolved for months, investigations hold up batch releases, and senior management is increasingly drawn into firefighting rather than driving manufacturing performance.
The study found that every plant surveyed had a backlog of incidents awaiting closure, with some investigations taking as long as six months. Nearly 80% of respondents said open investigations directly delayed batch releases, while senior leaders reported spending up to 27% of their time managing these backlogs.
The findings raise questions about whether India's pharmaceutical manufacturing operations can scale efficiently without addressing the growing burden of incident management and investigations.
The study suggests that recurring manufacturing incidents are not simply isolated operator failures. The way production work is documented, supervised and investigated could itself be contributing to the problem.
Human errors accounted for 56% of reported production incidents. Operators were found to make an average of 120 entries in Batch Production Records (BPRs) during every shift. The supervisory burden is equally significant: 80% of supervisors oversee five or more production lines per shift, potentially leaving limited time to verify processes, monitor execution and identify problems before they escalate.
“The real test of a robust quality system [SM1] is not how much documentation it generates, but whether it helps prevent errors and resolve deviations without disrupting production. That requires looking beyond individual incidents to understand why they keep occurring. When the underlying work processes are difficult to execute or verify, adding more checks may not address the root cause,” said Chandrachur Datta, Partner and co-author of the white paper at Vector Consulting Group.
The problem does not end with the occurrence of an incident. The process of investigating and closing it is emerging as another major source of operational delays.
Around 83% of respondents reported multiple revisions to investigation drafts, while 77% cited delays in evidence capture as a reason for information gaps. Another 73% said conflicting functional priorities contributed to delays or rework in closing investigations.
The findings suggest that investigations are being slowed down not just by the complexity of incidents, but also by gaps in evidence collection, repeated documentation and coordination challenges between departments.
Capturing evidence closer to the time an incident occurs, simplifying investigation workflows and speeding up reviews could help manufacturers reduce the time lost in closing deviations.
The white paper identifies two critical priorities for pharmaceutical manufacturers: preventing new incidents from entering the system and clearing existing investigation backlogs faster.
According to the study, the proposed interventions could reduce new incident generation by 30%-50%, while a structured investigation approach could cut closure timelines by 20%-40% for existing incidents.
Early capture of incident evidence can support more thorough investigations and faster closure. More importantly, addressing the underlying causes of recurring incidents could help manufacturers move away from reactive compliance management towards proactive quality management and sustained audit readiness.
For an industry aiming to reach $130 billion by 2030, the challenge is no longer just about expanding manufacturing capacity. It is also about ensuring that production runs smoothly, batches are released faster and plants remain consistently prepared for USFDA inspections.
Unless manufacturers tackle the operational drag created by recurring incidents and investigation backlogs, the compliance burden could become a significant obstacle to scaling India's pharmaceutical ambitions.
